Summary In a prospective randomised study 68 
The outcome of treatment of patients with small cell lung cancer remains guarded. Even when the disease is initially of limited extent, median survival is approximately [12] [13] [14] [15] months with less than 10% of patients achieving long-term disease-free survival (Bunn et al., 1987; Osterlind et al., 1986) . The contribution of maintenance chemotherapy to the outcome in those patients who achieve some degree of disease control following initial treatment is unclear, as is its role in the management of complete responders who may have the potential for long-term survival (Bleechen et al., 1986; Einhorn et al., 1987; Ettinger et al., 1987; Harper et al., 1987; Splinter et al., 1986; Woods and Levi, 1984) .
We report the results of a controlled clinical trial in which patients achieving complete remission, partial remission or disease stabilisation following initial treatment were randomly assigned to maintenance chemotherapy or to observation. The At the time of entry into the study, patients were randomly assigned to one of two treatment arms, maintenance or non-maintenance. Each arm consisted of initial treatment with three courses of alternating cycles of non-cross-resistant chemotherapy. After the first and second course, patients received radiotherapy to the primary site, mediastinum and, if involved, ipsilateral supraclavicular lymph nodes. Following this initial treatment, which lasted approximately 26 weeks, patients were restaged. Restaging involved repeating all the staging procedures including bronchoscopy and bronchoscopic biopsy. In addition, all patients found to be otherwise in complete remission had a cerebral CAT scan. Those in complete remission, partial remission or with stable disease who had been assigned to maintenance therapy then received a further six cycles of chemotherapy ( Figure 1 ). Prophylactic cranial radiotherapy was given to all those in complete remission.
The management of those whose disease progressed during initial treatment, who relapsed following initial complete and partial remission, or who had stable disease was not specified in the protocol and was at the discretion of the clinician.
Patients gave written informed consent and the study was approved by the Committee for Human Rights of the University of Western Australia.
Induction therapy
The initial combined chemotherapy and split course radiotherapy induction schedule was identical for each arm of the study (Figure 1 In all, three courses of this 7-week chemotherapy programme were given. The first moiety of thoracic radiotherapy (see below) began on day 50 of the first course of chemotherapy and was complete in 21 weeks (Figure 1 ).
The second course of chemotherapy began immediately after the first moiety of radiotherapy was completed. The second moiety of radiotherapy began on day 50 of the second course of chemotherapy and the third course of chemotherapy began immediately following completion of the thoracic radiotherapy.
Those assigned to maintenance chemotherapy received a further six cycles of CVM at 4 weekly intervals beginning immediately after restaging.
Drug doses were modified because of haematological toxicity on the basis of white cell and platelet counts on the day of therapy. If the white cell count was > 3 x 109 1 and the platelet count was 100 x 109 1-1, full doses of cyclophosphamide, VP 16213 and methotrexate were given. Doses were reduced to 75% of calculated dose for total white cell counts of 2.5-2.9 x 1091-1 and platelet counts of 75-99 x 1091-1. Treatment was delayed until counts reached appropriate levels if the white cell count was <2.5 x 109 1-or platelet count was <75 x 19 -1.
Vincristine was given in full dose calculated for surface area. Vincristine and cisplatinum dosages were not modified because of myelosuppression but administration was delayed if myelosuppression resulted in delay in administration of other drugs. Delivery of the radiotherapy induction regimen was delayed until the white cell count was >3.0 x 109 -1 and the platelet count was > 100 x 1091-1. Myelosuppression did not delay delivery of prophylactic cranial irradiation. Modifications were also made for mucosal toxicity, renal toxicity, neurotoxicity and auditory toxicity. In the presence of severe cyclophosphamide cystitis, chlorambucil was substituted for cyclophosphamide.
Radiotherapy
Radiotherapy was directed to the primary lesion, mediastinum and, if clinically involved, ipsilateral supraclavicular nodes. Megavoltage beams were used. The area of the field below the clavicles was not to exceed 150 cm2. A dose of 25 Gy in 13 fractions over 21 weeks was given after the first and second course of chemotherapy, giving a total dose of 50Gy divided into two equal moieties of 25 Gy, 7 weeks apart. The method of delivery of the first moiety was by parallel opposed ports. The second was given by a similar method or by a three-field technique at the radiotherapist's discretion. Treatment of the supraclavicular fossa involved a single anterior field in continuity with the mediastinal field using similar parameters of dose and delivery. A posterior parallel field with shielding was? optional.
Prophylactic cranial irradiation in a dose of 30Gy in 15 fractions over 3 weeks by lateral parallel opposed fields to encompass the entire intracranial contents was given to all patients who were in complete remission after restaging at the end of initial treatment. In those receiving maintenance chemotherapy prophylactic cranial irradiation and maintenance therapy were given concomitantly.
Response criteria and analysis Standard response criteria (Miller et al., 1981) were used except that patients were only assessed for complete response at the end of initial therapy and restaging which included bronchoscopy with biopsy or bronchial brushings.
Patients who appeared clinically free of disease during initial therapy but whose disease progressed before restaging were not considered to be complete responders.
Survival time was measured from the date of randomisation until death or last follow-up. Progression-free survival was measured from the date of randomisation until progression or death without progression. Patients who died without recurrence or progression of tumour were not censored from the analysis of progression-free survival, i.e. they were assumed to have died of tumour despite no evidence of progression or recurrence before death.
Toxicity related to treatment was graded according to WHO criteria (Miller et al., 1981) .
Survival curves were prepared by the method of Kaplan and Meier and the curves compared using the log rank test Kaplan & Meier, 1958; Peto et al., 1977) . The effect of the prognostic variables, maintenace, sex, age, tumour size and location on survival time and time to first progression were analysed using Cox's proportional hazards models (Cox, 1972) . Confidence intervals for the median survival were calculated using the method of Brookmeyer and Crowley (1982) .
Results
Sixty-eight patients were entered into the study and randomised. Two were found to be ineligible, one with nonsmall cell lung cancer and one with a past history of malignant melanoma. The clinical characteristics of the 66 eligible patients are shown in Table I . An estimate of th,e Five patients developed leukopenia of, <2 x 1091-1 on at least one occasion. There were no serious infections. Grade 3 gastrointestinal toxicity occurred in only 18% of cases. Three patients, however, refused maintenace therapy and six withdrew before the six cycles were complete. The intensity of chemotherapy given during the induction phase to those randomised to each arm of the study was calculated to detect possible imbalance in the groups. Figure  3 shows the percentage of patients who received 80% or more of the ideal scheduled dose for each of the three induction courses. No imbalance was detected. Those randomised to receive maintenance therapy received the same intensity of induction chemotherapy as those randomised to no maintenance.
;30-4 f%f^D iscussion In this study patients randomised to maintenance therapy had a significantly inferior survival to that of those receiving induction therapy alone. Deaths in the maintenace treated group were predominantly due to uncontrolled small cell cancer and not to toxicity of the maintenance therapy. While other studies have shown limited -or no advantage to maintenance chemotherapy, a significant adverse effect has not been seen (Table V) .
The median survival of 15.8 months for all treated patients and 25 months for those who achieved complete remission is comparable to that of other groups of patients with limited small cell cancer so treated (Bunn et al., 1987) . Those managed with the induction treatment programme alone, however, had a median survival of 19.2 months and 48% were relapse-free at 2 years, which is superior to that generally reported for such patients.
Had maintenance therapy merely failed to improve the results achieved by the initial therapy, it may have indicated that median survivals of 18-20 months are close to the limits of what can be achieved with current conventional chemotherapy and radiotherapy and that prolonging such treatment will not add significantly to the result. The apparent detrimental effect of maintenance therapy is not easily explained on this basis in the absence of evidence of toxicity leading to premature deaths.
The delivery of maintenance chemotherapy may have influenced the amount of chemotherapy given after relapse as relapse therapy was not specified in the protocol. If those who had not received maintenance therapy were able to receive more chemotherapy after relapse than those who had, this may have had a favourable influence on the survival of the non-maintenance group. To examine this possibility, the total drug dose and dose intensity of drug delivery after relapse was assessed in all patients who achieved complete remission. There were no significant differences between the groups. The reason for the significantly inferior survival of those randomised to maintenance therapy is therefore unclear.
Given the small numbers of patients accrued to this study, the absence of a clear explanation for the inferior survival of the maintenance group and the marginal significance of the difference, it is probably wisest to interpret the data as showing no benefit for maintenance chemotherapy. Viewed in this way the results are complementary to those of other larger studies addressing this question (Table V) .
Progression outside the irradiated field was the site of primary failure in 49% of cases, indicating that failure of chemotherapy to control metastases remains the major weakness of combined modality therapy. This study provides no encouragement that prolonging treatment with maintenance regimens of the type used will produce significant benefit. Other such studies (Table V) have also shown little or no evidence of benefit. It seems unlikely then that protocols relying on increasing the duration of chemotherapy with currently available agents will produce a quantum change in control outside of the irradiated field. Those in which a single combination is used during induction may improve outcome by incorporating a noncross-resistant regimen as consolidation (Einhorn et al., 1987) , but if alternating non-cross-resistant regimens are used during induction no extra benefit accrues with prolonged therapy.
In 12% of our patients the site of first progression was within the irradiated field. This is a somewhat lower figure than reported in trials of similar design (Perez et al., 1984; Perry et al., 1987) . As the toxicity of the radiotherapy dose and schedule used was low, the prospect exists for a small improvement in local control by modification of the radiotherapy programme.
Of the patients who achieved complete remission only two relapsed in the central nervous system, implying that prophylactic cranial irradiation as delivered provides sufficient protection against central nervous system relapse. If the overall treatment becomes more successful in the future late central nervous system relapse may become more prominent.
The basic strategy of the induction regimen of alternating cycles of non-cross-resistant chemotherapy with split course radiotherapy and prophylactic cranial irradiation for those in complete remission has produced a complete remission rate of 59% with 48% two-year disease-free survival in those not receiving maintenance therapy. The changes to the dose and scheduling of thoracic radiotherapy may produce an incremental improvement but a significant improvement in the degree of control of metastatic disease will be required to improve long-term outlook. It seems unlikely that maintenance chemotherapy will produce such benefit.
